Domestic pharmaceutical companies announced: Hengrui, Howson, Yangzijiang...

Torreya, the global investment bank, recently released the Global 1000 Pharmaceutical Companies Report, which provides a summary of the global pharmaceutical industry in September 2020 and compares it to the industry in 2015.
found that the rapid growth of China's pharmaceutical industry, explosive growth in biotechnology and increased importance in animal health have contributed to the democratization of the industry.
The importance of "big pharmaceutical companies" is now less important than it was five years ago, with the top 18 accounting for 77 per cent of the industry in 2003 and 54 per cent of the industry's value in 2015, compared with less than 50 per cent today.
the world's top 1,000 pharmaceutical companies have annual revenues of more than $1.2 trillion, according to estimates, the total value of the global pharmaceutical industry today is $6.65 trillion.
addition, many key trends are evident in the analysis of the world's top 1000 pharmaceutical companies.
1, The rapid rise of China's pharmaceutical industry.
the past decade, the Chinese government has consciously made a number of efforts to modernize the pharmaceutical industry and make innovative drugs accessable.
, Chinese pharmaceuticals added more than $350 billion in output and grew by about 100 percent during that time, a major change in the rankings.
2, high-growth biotechnology.
has achieved tremendous value growth in the U.S., Europe and especially Asia.
value of the biotechnology industry has increased by more than $250 billion in just five years.
biotechnology now accounts for 6.3 per cent of the total value of the pharmaceutical industry, compared with just 3 per cent in 2015.
3, the rapid development of biological agents also small molecules at the expense.
50 years ago, almost the entire pharmaceutical industry is built around small molecules and natural products.
in 2003, about 10 per cent of the industry included a variety of biological agents in terms of value.
by 2015, companies focused on biologics accounted for about a fifth of the industry's value.
today, these biologics account for one-third of the industry's value, while small molecules account for less than 60 percent of the industry's value.
, one of five extraordinary examples, is understood to be China's top 208 of the 1,000 companies.
among them, Hengrui ranked 21st in the world, and is the only domestic company to enter the global TOP25.
below is a picture of a Chinese pharmaceutical company among the world's top 100 pharmaceutical companies: (Photo: Maple Health) Notably, Torreya says the pharmaceutical industry has hundreds of impressive value creation stories, one of which is China's Hengrui Pharmaceuticals.
Hengrui had a market capitalisation of $279 million in 2003.
today, it's worth $71 billion.
more than 250 times.
company has brought cancer drugs to China when needed.
not mergers and acquisitions, but success with pure in-house innovation and a strong business team all over China.
, Hengrui is actively diversifying into over-the-counter and other therapeutic products that are not yet Chinese among consumers.
These pharmaceutical companies, ranked in the world's top 50 in addition to Hengrui, Yangzijiang, Shi Pharmaceutical Group, Zhifei Bio, Howson Pharmaceuticals, Qilu Pharmaceuticals, China Biopharmaceuticals, Changchun High-new, ChipPharmaceuticals and Colum Pharmaceuticals ranked in the world's top 50, basically compared to last year have a more obvious leap.
Pharmaceuticals (27): This is a true pharmaceutical giant and the highest-paid chinese pharmaceutical company.
Torreva valued the business at $44 billion.
, Yangzijiang Pharmaceuticals now has more than 16,000 employees and many important businesses.
20,000,000 square feet of operating space, the main plant in Taizhou is one of the largest pharmaceutical sites in the world, compared to other large industrial parks such as Amjin and Novartis.
Yangzijiang Pharmaceuticals has 20 subsidiaries in Beijing, Shanghai, Nanjing and Guangzhou, and has established research and development and production bases for innovative chemicals, patented Chinese medicine (TCMS) and biopharmaceuticals.
Group (30): The drug company ranked 68th in 2019, up 38 places.
, Stone Pharmaceuticals has rapidly transformed it into one of China's most innovative pharmaceutical companies, even though it has been a major industrial producer of vitamins, according to a recent report.
now, more than half of its profits come from innovative products, and Stone Pharmaceuticals' efforts are only just beginning.
company's research and development team of more than 900 employees has developed nearly 200 candidates dedicated to innovative treatments for central nervous system diseases, diabetes and infectious diseases.
Group has six independent research centers, seven national R.D. platform certifications, and outstanding clinical and regulatory capabilities.
, it is the first company in China to introduce a variety of new biologics, and one of the first Chinese pharmaceutical companies to apply for NDA in the United States.
majority of the investments in two U.S. biotech companies, Alamab Therapeutics and Novorock, have given them the ability to innovate and develop "large pharmaceutical" biologics and bring best-in-class, potentially best-in-class molecules to market.
Zhifei Bio (32): 75 in 2019, up 43 places.
reported that Zhifei is China's most important vaccine supplier, with a wealth of independently developed vaccine portfolios.
approved vaccines include meningococcal group A and Cand Haemophilus influenzae b combined vaccine, Haemophilus influenzae type b vaccine, ACYW135 meningococcal polysaccharide vaccine (Menway) and A, C meningococcal conjugate vaccine (Ming Acon).
as an agent to promote vaccines in China and established the industry's largest vaccine marketing network system.
Pharmaceuticals (37): It is understood that Howson was not on the list last year and is valued at $26 billion this year, ranking 37th in the world.
in general, this year's Chinese pharmaceutical companies have made great progress compared with the past, the rapid rise in the global ranking, can be a side of the rapid development of China's pharmaceutical industry.
2020 Global Pharmaceuticals TOP1000: (Photo: Medberg Health)